News
Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders
News
Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders
Read time:
Want a FREE PDF version of This News Story?
Complete the form below and we will email you a PDF version of "Oncolytics Biotech® Announces Issuance of 35th U.S. Patent for Cellular Proliferative Disorders"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
Oncolytics Biotech Inc. has announced that it has been granted its 35th U.S. Patent, No. 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."
The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.
Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.
The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
"This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of different cancers," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.
Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic reovirus.
Advertisement
